概括
新的KRAS G12D抑制剂正在出现,为胰腺,结直肠和肺癌提供了希望. 这些创新疗法针对以前"无法治疗"的突变,旨在改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 克拉斯G12D突变是胰腺癌,结直肠癌和非小细胞肺癌的关键驱动因素.
- 这种突变被认为是"不可抗药的",因为它缺乏反应部位,导致PI3K/AKT通路激活和免疫抑制瘤微环境.
研究的目的:
- 审查针对KRAS G12D突变的治疗策略的最新进展.
- 讨论新型抑制剂设计,临床试验进展以及克服耐药性的挑战.
主要方法:
- 小分子抑制剂的概述,包括非共价和共价方法.
- 探索替代模式,如蛋白质溶解向金马 (PROTACs),抑制剂和单体.
- 对临床试验数据的评估和对抗性机制的讨论.
主要成果:
- 使用离子相互作用开发高度选择性的非共价抑制剂 (例如,MRTX1133).
- 新型共价策略的出现,如应变释放化和三复合抑制剂 (例如,RMC-9805).
- 针对KRAS G12D向疗法的临床试验进展.
结论:
- 在开发可用药物的KRAS G12D抑制剂方面取得的重大进展正在重塑癌症治疗.
- 未来的方向包括优化药物输送和组合疗法,以提高疗效和耐用性.
- 解决获得的耐药性对于长期的临床成功至关重要.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.5K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.3K
相关概念视频
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Small GTPases - Ras and Rho
5.1K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
